Share on StockTwits

Mallinckrodt PLC (NYSE:MNK) has earned a consensus rating of “Buy” from the thirteen ratings firms that are currently covering the stock, Analyst Ratings.Net reports. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $86.36.

MNK has been the subject of a number of recent research reports. Analysts at Bank of America raised their price target on shares of Mallinckrodt PLC to $97.00 in a research note on Tuesday, July 29th. Separately, analysts at Deutsche Bank initiated coverage on shares of Mallinckrodt PLC in a research note on Tuesday, July 22nd. They set a “buy” rating and a $96.00 price target on the stock. Finally, analysts at Jefferies Group raised their price target on shares of Mallinckrodt PLC from $85.00 to $95.00 in a research note on Monday, July 21st. They now have a “buy” rating on the stock.

Mallinckrodt PLC (NYSE:MNK) opened at 69.89 on Wednesday. Mallinckrodt PLC has a 52 week low of $41.67 and a 52 week high of $83.20. The stock’s 50-day moving average is $76.06 and its 200-day moving average is $69.87. The company has a market cap of $4.093 billion and a P/E ratio of 64.58.

Mallinckrodt PLC (NYSE:MNK) last announced its earnings results on Thursday, May 8th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.17. The company had revenue of $557.80 million for the quarter, compared to the consensus estimate of $566.50 million. The company’s revenue for the quarter was down 4.7% on a year-over-year basis. On average, analysts predict that Mallinckrodt PLC will post $3.53 earnings per share for the current fiscal year.

Mallinckrodt public limited company (NYSE:MNK) is a global specialty pharmaceuticals company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.